Chromocell Therapeutics Profit Margin

The latest profit margin for CHRO is -1.86% as of March 2026. That is below the sector sector average of 19.72%. Investors often review this figure alongside Chromocell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, CHRO currently prints -1.86% for profit margin, while the sector average sits near 19.72%. That is roughly 1044.4% below the sector mean. Large gaps often invite a closer look at Chromocell Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Chromocell Therapeutics converts resources into returns. At -1.86%, CHRO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CHRO's profit margin (-1.86%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.